FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis

In April 2017, the U.S. Food and Drug Administration granted regular approval to midostaurin for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM‐AHN), or mast cell leukemia (MCL). Approval was based on resu...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Kasamon, Yvette L., Ko, Chia‐Wen, Subramaniam, Sriram, Ma, Lian, Yang, Yuching, Nie, Lei, Shord, Stacy, Przepiorka, Donna, Farrell, Ann T., McKee, Amy E., Pazdur, Richard
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2018
Onderwerpen:
Regulatory Issues: FDA
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6292539/
https://ncbi.nlm.nih.gov/pubmed/30115735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0222
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items